| 1 Leaving the study early: 1. Any reason |
2 |
130 |
Risk Ratio (M‐H, Random, 95% CI) |
1.87 [0.48, 7.23] |
| 1.1 short term |
2 |
130 |
Risk Ratio (M‐H, Random, 95% CI) |
1.87 [0.48, 7.23] |
| 2 Leaving the study early: 2. Due to adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 short term |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
2.6 [0.31, 22.05] |
| 3 Mental state: 1. State ‐ less than 30% BPRS reduction ('no effect') |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 3.1 short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
2.55 [0.52, 12.52] |
| 4 Mental state: 2. State ‐ BPRS end score (high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.1 total score ‐ short term |
1 |
102 |
Mean Difference (IV, Random, 95% CI) |
0.94 [‐1.49, 3.37] |
| 4.2 anxiety‐depression score ‐ short term |
1 |
102 |
Mean Difference (IV, Random, 95% CI) |
0.92 [0.34, 1.50] |
| 5 Adverse events: Movement disorders |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 dyskinesia ‐ short term |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 5.2 hyperkinesia ‐ short term |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 5.3 myotony ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
21.43 [1.29, 355.77] |
| 5.4 rigidity ‐ short term |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
6.13 [0.35, 108.58] |
| 5.5 tremor ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
5.10 [1.18, 22.09] |
| 6 Other adverse events: 1. Anticholinergic |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 blurred vision ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.85 [0.49, 1.49] |
| 6.2 dry mouth ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
4.59 [1.68, 12.58] |
| 6.3 increased salivation ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.05 [0.01, 0.20] |
| 7 Other adverse events: 2. Arousal |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 drowsiness ‐ short term |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
0.43 [0.20, 0.94] |
| 7.2 excitement ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
21.44 [3.00, 153.14] |
| 7.3 somnolence ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.19 [0.07, 0.52] |
| 7.4 restlessness ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
5.10 [1.88, 13.83] |
| 8 Other adverse events: 3. At least one |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 short term |
1 |
28 |
Risk Ratio (M‐H, Random, 95% CI) |
2.6 [0.31, 22.05] |
| 9 Other adverse events: 4. Cardiovascular |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 9.1 dizziness ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.92 [0.56, 1.51] |
| 9.2 tachycardia ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.23 [0.13, 0.42] |
| 10 Other adverse events: 5. Gastrointestinal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 10.1 constipation ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.20, 0.54] |
| 11 Other adverse events: 6. Lab data |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 11.1 abnormal EKG ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
1.33 [0.73, 2.44] |
| 11.2 high white blood cell count ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
1.02 [0.07, 15.86] |
| 11.3 low white blood cell count ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.17 [0.02, 1.36] |
| 11.4 liver function (GPT+) ‐ short term |
1 |
97 |
Risk Ratio (M‐H, Random, 95% CI) |
0.58 [0.18, 1.86] |
| 12 Other adverse events: 7. Average endpoint score (TESS, skew) |
|
|
Other data |
No numeric data |
| 12.1 short term |
|
|
Other data |
No numeric data |
